Leaky Gut and Pulmonary Fibrosis: Is There Scientific Evidence?
Could a problem in the intestinal barrier influence what happens in the lungs?
It may sound surprising, especially in a disease such as pulmonary fibrosis, where the most visible pathology occurs deep within the lung.
Yet this question is increasingly being investigated.
The intestine contains trillions of microorganisms and has one of the largest interfaces between the external environment and the immune system. A highly regulated intestinal barrier normally separates this microbial ecosystem from the systemic circulation.
When that barrier becomes dysfunctional, microbial products may gain greater access to the bloodstream.
This phenomenon is often described as increased intestinal permeability and is commonly referred to outside scientific literature as “leaky gut.”
Researchers are now studying whether intestinal-barrier dysfunction could contribute to diseases far beyond the gastrointestinal tract.
Pulmonary fibrosis is one of them.
Experimental pulmonary fibrosis studies have demonstrated intestinal microbiome disruption, changes in tight-junction proteins and evidence of intestinal-barrier dysfunction. A major 2025 review of the lung–gut axis identified barrier dysfunction as one of five core mechanisms potentially linking microbial dysbiosis with pulmonary fibrosis. (Frontiers)
But there is an important limitation.
Most direct evidence connecting increased intestinal permeability with pulmonary fibrosis comes from animal and mechanistic studies—not from patients with idiopathic pulmonary fibrosis.
This distinction matters.
It means we can reasonably discuss leaky gut as an emerging biological hypothesis in pulmonary fibrosis.
We cannot currently say that leaky gut causes IPF or that repairing the intestinal barrier will stop or reverse pulmonary fibrosis.
So what does the evidence actually show?
What Does “Leaky Gut” Actually Mean?
The medical term most closely corresponding to “leaky gut” is:
increased intestinal permeability.
The intestine is lined by a single layer of epithelial cells.
These cells are joined together by structures known as tight junctions, which help control what passes from the intestinal lumen into the circulation.
Important tight-junction proteins include:
zonula occludens-1, or ZO-1
occludin
claudins
Under normal conditions, this barrier allows nutrients and selected molecules to cross while restricting excessive entry of:
bacteria
bacterial fragments
endotoxins
microbial antigens
other potentially inflammatory substances
When intestinal-barrier integrity becomes impaired, the movement of these substances across the intestinal lining may increase.
This is what researchers mean by increased intestinal permeability.
Is “Leaky Gut” a Diagnosis?
Not in the same way that conditions such as Crohn’s disease, celiac disease or ulcerative colitis are diagnoses.
The phrase leaky gut syndrome is often used very broadly in wellness and functional medicine settings.
That can create confusion.
Intestinal permeability is a real physiological phenomenon and can be measured in research settings.
But it is not currently an established explanation for every chronic inflammatory or autoimmune condition.
The important question is not whether intestinal permeability exists.
It clearly does.
The important question is:
Does abnormal intestinal permeability meaningfully contribute to a particular disease?
For pulmonary fibrosis, that question remains under investigation.
Why Might the Gut Barrier Matter to the Lungs?
The intestine and lungs communicate through the gut–lung axis.
This communication occurs through several systems:
immune cells
circulating inflammatory mediators
microbial metabolites
microbial components
bone-marrow immune responses
A simplified proposed pathway is:
Gut dysbiosis ↓ Reduced intestinal-barrier integrity ↓ Greater exposure to microbial products ↓ Systemic immune activation ↓ Pulmonary epithelial and immune-cell signaling ↓ Potential influence on fibrotic pathways
This pathway is biologically plausible.
But each step requires evidence.
What Is Pulmonary Fibrosis?
Pulmonary fibrosis refers to abnormal accumulation of scar tissue within the lungs.
In idiopathic pulmonary fibrosis, or IPF, the process appears to involve repeated injury to alveolar epithelial cells followed by abnormal repair.
Major biological processes include:
epithelial injury
cellular senescence
fibroblast activation
myofibroblast differentiation
TGF-β signaling
extracellular matrix deposition
collagen accumulation
Over time, normal lung architecture is progressively replaced by fibrotic tissue.
The key question is whether signals originating in the gut might modify this process.
What Does the Current Evidence Say?
Current evidence can be divided into three levels:
1. Human microbiome evidence
Patients with pulmonary fibrosis appear to have alterations in microbial communities.
2. Experimental evidence of intestinal-barrier dysfunction
Animal pulmonary fibrosis models show abnormalities in gut-barrier integrity.
3. Mechanistic evidence
Microbial products and metabolites can influence immune and profibrotic pathways.
The strongest evidence for intestinal permeability specifically currently comes from levels 2 and 3.
Human Evidence: The Gut Microbiome Is Associated With IPF
One important development came in 2026.
Researchers analyzed fecal microbial samples from 411 patients with idiopathic pulmonary fibrosis enrolled in the CleanUP-IPF study.
Gut microbiota were characterized using both 16S rRNA sequencing and shotgun metagenomic sequencing.
The investigators found that gut microbial composition was associated with clinical characteristics including:
age
sex
proton-pump inhibitor use
Importantly, microbial community features were also associated with percent predicted DLCO, an important measure of pulmonary disease severity.
Certain microbial features were additionally associated with transplant-free survival in selected analyses. (PubMed)
This provides strong evidence that the intestinal microbiome is associated with the clinical phenotype of human IPF.
But the study did not demonstrate that those patients had increased intestinal permeability.
That distinction is critical.
Gut Dysbiosis Is Not the Same as Leaky Gut
These terms are frequently used interchangeably, but they describe different biological processes.
Gut dysbiosis
refers to changes in microbial ecology.
Increased intestinal permeability
refers to impaired intestinal-barrier function.
Dysbiosis may contribute to barrier dysfunction.
Barrier dysfunction may also change the microbial ecosystem.
They may occur together.
But demonstrating dysbiosis does not automatically prove increased intestinal permeability.
Therefore, the large 2026 IPF microbiome study strengthens the evidence for a gut–IPF association, but it does not prove “leaky gut” in IPF.
What Do Animal Studies Show?
This is where the evidence becomes more direct.
A 2024 study evaluated intestinal microbiota and signaling pathways in a bleomycin-induced pulmonary fibrosis model.
The animals developed progressive lung injury and fibrosis together with:
altered intestinal microbial composition
abnormalities in PI3K/AKT signaling
abnormalities in NRF2/HO-1 signaling
intestinal-barrier dysfunction
The investigators concluded that experimental pulmonary fibrosis was associated with both intestinal dysbiosis and intestinal barrier disorder. (PubMed)
This is important because it demonstrates that pulmonary fibrosis and intestinal-barrier abnormalities can occur together in an experimental model.
But again, this was an animal model.
Tight-Junction Proteins in Experimental Pulmonary Fibrosis
Several pulmonary fibrosis models have examined the proteins that maintain intestinal-barrier integrity.
These include:
ZO-1
occludin
claudin-1
Experimental fibrosis has been associated with reduced expression of these proteins.
A 2024 mouse study investigating lung–gut crosstalk reported disruption of both pulmonary and intestinal barriers during bleomycin-induced fibrosis.
An experimental intervention improved expression of:
ZO-1
claudin-1
occludin
in addition to improving lung–gut immune and microbial abnormalities. (PubMed)
This supports the concept that barrier dysfunction can be part of experimental pulmonary fibrosis biology.
Why Do Tight Junctions Matter?
Tight junctions help regulate the passage of substances between intestinal epithelial cells.
If proteins such as ZO-1 and occludin decrease, the intestinal barrier may become more permeable.
That could theoretically allow more:
lipopolysaccharide
bacterial fragments
microbial DNA
metabolites
to enter systemic circulation.
These substances may then interact with the immune system.
The LPS Hypothesis
One of the most important molecules in this discussion is:
lipopolysaccharide, or LPS.
LPS is part of the outer membrane of Gram-negative bacteria.
When LPS reaches immune cells, it can activate receptors such as:
Toll-like receptor 4, or TLR4.
This can stimulate downstream inflammatory pathways including:
NF-κB
and increase production of inflammatory mediators.
A potential gut–lung pathway is therefore:
Gut dysbiosis → impaired barrier → increased LPS exposure → TLR4 activation → inflammatory signaling → pulmonary epithelial injury and fibroblast activation
A major 2025 lung–gut fibrosis review identifies LPS as one of the principal microbial mediators potentially linking gut-barrier dysfunction with pulmonary fibrosis. (Frontiers)
This mechanism is plausible.
It is not yet proven as a major driver of human IPF.
Could LPS Activate Fibroblasts?
Potentially.
TLR signaling can interact with pathways relevant to fibrosis.
These include:
NF-κB
inflammatory cytokines
macrophage activation
TGF-β-related signaling
Fibroblasts respond to their inflammatory and biochemical environment.
Under profibrotic conditions they may differentiate into myofibroblasts and produce greater amounts of extracellular matrix.
This provides a plausible bridge between microbial translocation and fibrotic signaling.
However, the presence of a plausible pathway does not establish how important that pathway is in patients.
The Gut Barrier and Systemic Inflammation
If intestinal permeability increases, systemic exposure to microbial signals may theoretically increase.
This could affect pulmonary immunity through:
circulating cytokines
monocyte recruitment
macrophage activation
T-cell responses
The lung–gut fibrosis literature has proposed that intestinal-barrier dysfunction can amplify inflammatory signaling involving mediators such as:
IL-6
IL-17
TNF-α
which may influence pulmonary inflammatory and fibrotic pathways. (Frontiers)
Again, much of this evidence is mechanistic or preclinical.
Treg and Th17 Cells
The intestinal microbiome strongly influences immune-cell differentiation.
Two immune populations of particular interest are:
regulatory T cells, or Tregs
and
Th17 cells.
Tregs generally help regulate excessive immune activity.
Th17 cells participate in mucosal defense but can contribute to pathological inflammation when dysregulated.
Changes in the gut microbiome and microbial metabolites may influence the balance between these populations.
A dysbiotic intestinal environment with reduced barrier integrity might theoretically favor more inflammatory immune signaling.
The 2025 pulmonary fibrosis review identifies dysregulated immune balance—including Th17-related pathways—as one mechanism linking microbiota with fibrosis. (PubMed)
Short-Chain Fatty Acids: The Other Side of the Barrier Story
Not all microbial products are potentially harmful.
Many gut bacteria generate metabolites that support intestinal-barrier integrity.
Among the most important are short-chain fatty acids, or SCFAs.
These include:
acetate
propionate
butyrate
SCFAs are produced when intestinal bacteria ferment dietary substrates.
They can influence:
intestinal epithelial cells
tight-junction proteins
Treg activity
macrophages
inflammatory signaling
Therefore, intestinal barrier health may depend not simply on preventing harmful bacteria from entering the bloodstream but also on maintaining adequate microbial metabolic function.
Butyrate and the Intestinal Barrier
Butyrate is particularly relevant.
It serves as an important energy source for colonocytes and can help support intestinal epithelial integrity.
Butyrate also influences immune and epigenetic pathways.
If dysbiosis reduces butyrate-producing microbial activity, intestinal-barrier function could theoretically weaken.
This creates another potential pathway:
Dysbiosis ↓ Reduced beneficial microbial metabolites ↓ Barrier impairment ↓ Greater inflammatory exposure ↓ Potential systemic and pulmonary effects
But this remains a mechanistic model.
There is no evidence that simply giving a patient butyrate will repair pulmonary fibrosis.
SCFAs and LPS May Work in Opposite Directions
The emerging literature suggests an important interaction.
SCFAs may help strengthen the intestinal barrier and reduce microbial translocation.
LPS, on the other hand, may promote inflammatory signaling.
The balance between these microbial signals may therefore be more relevant than the abundance of a single bacterial species.
This is one reason modern microbiome research is shifting from asking:
“Which bacteria are present?”
toward:
“What are those microbial communities producing?”
Tryptophan Metabolism May Also Influence the Barrier
Gut bacteria metabolize the amino acid tryptophan into multiple compounds.
Some of these activate the:
aryl hydrocarbon receptor, or AhR.
AhR signaling influences:
epithelial-barrier integrity
mucosal immunity
Treg/Th17 balance
Reduced production of beneficial AhR ligands could theoretically impair intestinal immune homeostasis.
At the same time, pulmonary fibrosis research has shown that tryptophan metabolism can influence fibrotic pathways.
For example, experimental work has demonstrated that tryptophan can promote fibroblast activation and epithelial–mesenchymal signaling through mTOR-related pathways in pulmonary fibrosis models. (Nature)
This demonstrates how gut microbial metabolism, immune regulation and fibrosis could potentially intersect.
The Gut Barrier May Affect the Lung Barrier
Another intriguing concept is that disruption may occur at more than one epithelial surface.
The intestine has a barrier.
The lung also has epithelial and endothelial barriers.
The 2025 pulmonary fibrosis gut–lung review proposes that increased systemic exposure to microbial products can influence pulmonary epithelial and vascular barrier integrity. (Frontiers)
This raises the possibility of a broader:
gut barrier–lung barrier axis.
However, it remains primarily mechanistic.
Lung Tight-Junction Abnormalities Are Better Established Than Gut Permeability in Human IPF
This is an important distinction.
Studies of human IPF lungs have demonstrated abnormalities in pulmonary epithelial tight-junction proteins.
This supports the concept of impaired lung epithelial barrier integrity in IPF.
But this should not be cited as evidence of intestinal permeability.
The lung barrier and gut barrier are different tissues.
One of the common mistakes in gut–lung discussions is to use evidence of altered lung tight junctions as proof that patients have leaky gut.
That conclusion is not justified.
Could the Lung Disease Cause the Leaky Gut Instead?
Yes.
This possibility deserves much more attention.
Suppose a patient with severe pulmonary fibrosis develops intestinal-barrier dysfunction.
It could be caused by the lung disease rather than causing the lung disease.
Advanced pulmonary disease can be accompanied by:
reduced physical activity
altered diet
hypoxemia
systemic inflammation
multiple medications
antibiotic exposure
proton-pump inhibitor use
All of these can potentially influence gastrointestinal physiology and microbial ecology.
Therefore, the relationship could be:
lung disease → gut dysfunction
rather than simply:
gut dysfunction → lung disease.
The most realistic model may be bidirectional.
Does Leaky Gut Cause IPF?
At present, there is no convincing human evidence that increased intestinal permeability causes idiopathic pulmonary fibrosis.
This statement should be very clear.
We have:
Strong biological plausibility
Yes.
Experimental evidence
Yes.
Evidence of altered gut microbiota in human IPF
Yes.
Large human data showing microbiome associations with disease severity
Yes. (PubMed)
Direct prospective human evidence showing intestinal permeability precedes and causes IPF
No.
That is the current evidence hierarchy.
Is Leaky Gut Associated With Other Fibrotic Lung Diseases?
The broader gut–lung literature includes other fibrotic disorders such as:
systemic sclerosis-associated ILD
rheumatoid arthritis-associated ILD
myositis-associated ILD
silicosis
coal workers’ pneumoconiosis
The evidence is particularly interesting in systemic sclerosis because gastrointestinal involvement, dysmotility and SIBO are common.
In such diseases, gut dysfunction may be clinically more prominent than in idiopathic pulmonary fibrosis.
But even there, demonstrating dysbiosis or gastrointestinal disease does not prove that intestinal permeability directly causes pulmonary fibrosis.
What About Systemic Sclerosis?
Systemic sclerosis is particularly relevant to the gut–lung hypothesis.
Patients may experience:
esophageal dysmotility
gastroparesis
small-intestinal dysmotility
SIBO
malabsorption
reflux
Human microbiome research has also identified intestinal microbial patterns associated with SSc-ILD.
This creates a biologically plausible interaction between:
**gut dysmotility
dysbiosis
immune dysfunction
pulmonary disease.**
But the pathway remains complex.
Scleroderma itself can damage both the gastrointestinal tract and lungs.
Therefore, gut abnormalities may be part of systemic disease rather than the primary cause of ILD.
Is Leaky Gut the Same as SIBO?
No.
These are different concepts.
SIBO
refers to abnormal bacterial overgrowth or microbial composition within the small intestine.
Increased intestinal permeability
refers to impaired intestinal-barrier integrity.
Gut dysbiosis
refers more broadly to alteration of microbial ecology.
A person could theoretically have:
dysbiosis without SIBO
SIBO without proven increased permeability
increased permeability without SIBO
They should not automatically be treated as interchangeable diagnoses.
Can Commercial Testing Diagnose Leaky Gut?
This requires caution.
Various laboratory tests have been promoted to evaluate intestinal permeability.
Some research methods assess passage of specific sugar molecules across the intestine.
Commercial testing may also measure markers such as:
zonulin
LPS-related markers
intestinal fatty acid binding protein
other proposed permeability markers
But none currently functions as an established pulmonary fibrosis biomarker.
There is no validated commercial test that can tell a patient:
“Your pulmonary fibrosis is being caused by leaky gut.”
What About Zonulin?
Zonulin is frequently discussed in functional medicine.
It is involved in regulation of intestinal tight junctions.
However, interpreting commercially measured zonulin is complicated.
Different laboratory assays may not necessarily measure the biologically relevant molecule with adequate specificity.
Therefore, a single elevated commercial zonulin value should not be used to conclude that intestinal permeability is causing pulmonary fibrosis.
Can Treating Leaky Gut Improve Pulmonary Fibrosis?
There is currently no clinical evidence that treating intestinal permeability:
improves FVC
improves DLCO
reverses fibrosis on HRCT
reduces progressive pulmonary fibrosis
improves transplant-free survival
This is the critical clinical limitation.
Improving gastrointestinal health may still be worthwhile.
But it should not be presented as a proven antifibrotic therapy.
What About Probiotics?
Probiotics may influence:
microbial composition
SCFA production
intestinal-barrier function
immune signaling
Animal pulmonary fibrosis experiments have produced encouraging results with selected strains.
But no probiotic has been proven to repair intestinal permeability and thereby slow human IPF.
Probiotic effects are also strain-specific.
One Lactobacillus strain cannot automatically be assumed to have the same effect as another.
What About Prebiotics and Fiber?
Dietary fiber can support microbial fermentation and production of short-chain fatty acids.
This can potentially support intestinal-barrier health.
However, there is no clinical trial showing that increasing fiber slows pulmonary fibrosis.
In addition, not every patient with ILD tolerates high amounts of fermentable fiber.
This is particularly relevant in people with:
significant bloating
SIBO
dysmotility
systemic sclerosis
severe reflux
Diet should therefore be individualized.
What About Butyrate Supplements?
Butyrate is one of the most interesting metabolites in barrier biology.
It may support:
colonocyte function
tight-junction integrity
Treg regulation
anti-inflammatory signaling
But oral butyrate supplementation has not been demonstrated to treat pulmonary fibrosis.
The evidence remains mechanistic and preclinical.
What About Glutamine?
Glutamine is often promoted for intestinal-barrier support.
It can serve as an energy substrate for intestinal epithelial cells and has been investigated in various gastrointestinal and critical illness settings.
But there is no evidence that glutamine supplementation modifies pulmonary fibrosis through intestinal-barrier repair.
It should not be marketed as an IPF treatment.
What About Fecal Microbiota Transplantation?
FMT can dramatically modify the intestinal microbial ecosystem.
Experimental studies have explored microbiota transfer in lung disease and pulmonary fibrosis models.
Some preclinical findings suggest that manipulating the gut microbiome can alter pulmonary inflammation and fibrosis.
However, FMT is not an established treatment for pulmonary fibrosis.
Its proven clinical applications are currently in very different gastrointestinal settings, particularly selected recurrent Clostridioides difficile infections.
Should Someone With Pulmonary Fibrosis Try to “Heal the Gut”?
The phrase can be misleading because it implies a universal protocol.
A more clinically useful question is:
Does this particular patient have a gastrointestinal problem that deserves evaluation and treatment?
Examples include:
persistent bloating
diarrhea
constipation
unexplained weight loss
malabsorption
reflux
dysphagia
suspected SIBO
medication-related gastrointestinal symptoms
These problems should be evaluated on their own merits.
Treating them may improve:
nutrition
comfort
food tolerance
quality of life
But this should not be confused with proven reversal of lung fibrosis.
Nutrition May Matter More Than Restrictive “Gut Healing” Diets
Pulmonary fibrosis can be associated with:
reduced appetite
weight loss
muscle loss
frailty
increased energy expenditure from breathing
A highly restrictive diet aimed at eliminating multiple foods may worsen these problems.
For many patients, the priorities include:
adequate protein
sufficient calories
maintaining muscle mass
appropriate dietary fiber when tolerated
correction of documented deficiencies
management of reflux or swallowing problems
The best gut strategy is not necessarily the most restrictive one.
GERD and Leaky Gut Are Different
Pulmonary fibrosis is commonly associated with gastroesophageal reflux.
The proposed pulmonary mechanism of reflux is mainly:
reflux → microaspiration → repeated exposure of the airway and alveoli
Leaky gut represents a different theoretical pathway:
intestinal barrier dysfunction → microbial products and metabolites → systemic circulation → pulmonary immune signaling
They may coexist.
But they should not be confused.
How Could the Gut Microbiome Influence Pulmonary Fibrosis Even Without Leaky Gut?
This is another important point.
The gut microbiome does not require a severely damaged intestinal barrier to influence the lungs.
Microbial metabolites can normally enter circulation and act on distant organs.
Examples include:
SCFAs
tryptophan metabolites
bile-acid metabolites
These molecules can influence immune cells throughout the body.
Therefore, the gut–lung axis is broader than leaky gut.
Focusing exclusively on permeability may oversimplify the biology.
Five Major Ways the Microbiome May Influence Lung Fibrosis
Current research suggests that the microbiome may influence pulmonary fibrosis through several overlapping mechanisms.
1. Immune dysregulation
Changes in Tregs, Th17 cells, macrophages and inflammatory cytokines.
2. Barrier dysfunction
Altered intestinal and pulmonary epithelial integrity.
3. Microbial metabolites
Changes in SCFAs, tryptophan derivatives and bile acids.
4. Autophagy and cellular signaling
Microbial signals may influence PI3K/AKT/mTOR and related pathways.
5. Alveolar epithelial injury
Microbial products and peptides may contribute to epithelial injury and apoptosis.
A 2025 review identified these mechanisms as central components of the emerging microbiota–pulmonary fibrosis model. (Frontiers)
What We Know
Current evidence supports several conclusions.
We know that:
pulmonary fibrosis is associated with altered microbial ecosystems
a large 2026 human IPF study found associations between gut microbiota and disease severity
experimental pulmonary fibrosis can be accompanied by intestinal-barrier dysfunction
tight-junction proteins such as ZO-1 and occludin are altered in several animal models
microbial products such as LPS can activate systemic immune pathways
SCFAs and tryptophan metabolites can influence barrier and immune function
gut-barrier dysfunction is biologically plausible as part of the lung–gut axis
(PubMed)
What We Do Not Know
We do not know:
whether increased intestinal permeability occurs consistently in human IPF
whether it appears before pulmonary fibrosis begins
whether it predicts disease progression
whether it independently influences FVC or DLCO
whether repairing the gut barrier changes pulmonary outcomes
whether commercial permeability tests identify meaningful IPF phenotypes
whether probiotics, butyrate or other barrier-directed treatments modify survival
These are major gaps in the evidence.
What Does This Mean Clinically?
The practical interpretation should be cautious.
If a patient with pulmonary fibrosis has significant gastrointestinal symptoms, these should be evaluated and treated appropriately.
This may include assessment of:
reflux
swallowing dysfunction
bowel symptoms
nutritional status
SIBO when clinically suspected
malabsorption
medication-related gastrointestinal effects
But a diagnosis of pulmonary fibrosis alone does not mean the patient has leaky gut.
And it does not automatically justify extensive permeability testing or supplement protocols.
Functional and Integrative Medicine Perspective
The gut–lung axis provides a useful framework for looking beyond the lung without abandoning established pulmonary medicine.
A comprehensive assessment may include:
gastrointestinal symptoms
diet
nutritional adequacy
metabolic health
weight and muscle mass
reflux and aspiration risk
physical activity
sleep
environmental exposures
Where clinically indicated, specific gastrointestinal abnormalities can be evaluated.
The goal should be to improve the patient’s overall health and address relevant comorbidities.
It should not be to claim that pulmonary fibrosis can be reversed simply by “sealing the gut.”
What Treatment Still Matters Most?
Evidence-based pulmonary care remains central.
Depending on the type and severity of fibrosis, this may include:
antifibrotic treatment
immunomodulatory therapy for appropriate autoimmune ILD
pulmonary rehabilitation
oxygen therapy
vaccination
treatment of comorbidities
smoking cessation
lung transplantation evaluation when indicated
Gut-directed interventions should never delay appropriate specialist pulmonary treatment.
Where Is the Research Going?
Future research needs to move beyond simple stool bacterial profiles.
Ideally, studies should combine:
**gut metagenomics
intestinal-permeability measurements
microbial metabolomics
immune profiling
pulmonary function
HRCT progression
long-term outcomes**
Researchers need to determine whether intestinal-barrier dysfunction:
occurs before pulmonary fibrosis progresses
predicts clinically meaningful outcomes
can be modified
changes pulmonary outcomes when corrected
Without that sequence, leaky gut will remain an interesting mechanism rather than a validated therapeutic target.
Frequently Asked Questions
Can leaky gut cause pulmonary fibrosis?
There is currently no direct human evidence proving that increased intestinal permeability causes pulmonary fibrosis.
Animal and mechanistic studies support biological plausibility, but causality has not been established.
Is leaky gut common in IPF?
We do not currently know.
Gut microbiome abnormalities have been identified in IPF, but large human studies directly measuring intestinal permeability are lacking.
Is there evidence that the gut affects pulmonary fibrosis?
Yes.
Human studies show associations between gut microbial composition and IPF severity, while animal studies demonstrate microbiome, barrier and metabolic abnormalities during pulmonary fibrosis. (PubMed)
Does healing the gut reverse pulmonary fibrosis?
There is no clinical evidence that repairing intestinal permeability reverses established pulmonary fibrosis.
Can probiotics help pulmonary fibrosis?
Probiotics have shown interesting effects in experimental models, but no probiotic is currently proven to slow or reverse human IPF.
Can butyrate repair the gut and improve lung fibrosis?
Butyrate can support intestinal-barrier and immune function, but there is no adequate clinical evidence showing that butyrate supplementation improves pulmonary fibrosis.
Should patients with IPF test zonulin?
There is no validated role for commercial zonulin testing in determining the cause, severity or treatment of IPF.
Is leaky gut the same as dysbiosis?
No.
Dysbiosis refers to altered microbial ecology.
Leaky gut refers to increased intestinal permeability.
The two may be related but are not interchangeable.
Is leaky gut the same as SIBO?
No.
SIBO refers to abnormal microbial growth in the small intestine.
Intestinal permeability refers to barrier function.
They are distinct conditions.
Can diet support the intestinal barrier?
Diet can influence gut microbial composition and microbial metabolites.
A nutritionally adequate diet containing appropriate amounts of fiber may support gut health in many people, but no specific diet is proven to treat pulmonary fibrosis by repairing the intestinal barrier.
Key Takeaway
The most accurate interpretation of the evidence is:
Intestinal-barrier dysfunction is a plausible component of the gut–lung axis in pulmonary fibrosis and is supported by experimental studies, but direct evidence that “leaky gut” causes or drives human idiopathic pulmonary fibrosis remains limited.
Conclusion
The possibility that leaky gut and pulmonary fibrosis are connected is scientifically credible—but the evidence needs to be interpreted carefully.
Animal models of pulmonary fibrosis demonstrate:
gut dysbiosis
disruption of intestinal tight-junction proteins
intestinal-barrier dysfunction
altered microbial metabolites
systemic immune abnormalities
These findings support a potential pathway in which intestinal-barrier dysfunction permits greater exposure to microbial products such as LPS, amplifying immune signals that may affect the lungs. (PubMed)
At the same time, microbial metabolites such as:
butyrate
other short-chain fatty acids
tryptophan derivatives
bile-acid metabolites
may influence both intestinal-barrier health and pulmonary immune signaling.
Human evidence also supports a gut–lung connection.
In 2026, analysis of 411 patients with idiopathic pulmonary fibrosis demonstrated associations between gut microbial composition, pulmonary disease severity and transplant-free survival. (PubMed)
But that study did not prove increased intestinal permeability.
This distinction is essential.
At present, we can reasonably say:
the gut microbiome is associated with pulmonary fibrosis.
We can also say:
intestinal-barrier dysfunction can accompany pulmonary fibrosis in experimental models.
What we cannot yet say is:
leaky gut causes IPF.
And we cannot say:
repairing leaky gut treats or reverses pulmonary fibrosis.
Future studies should directly measure intestinal permeability in well-characterized patients with IPF and other forms of ILD, integrate those findings with microbiome and metabolomic data, and determine whether barrier abnormalities predict pulmonary progression.
Only then will we know whether intestinal permeability is:
a cause
a consequence
a disease modifier
a biomarker
or some combination of these.
For now, gastrointestinal health remains an important component of comprehensive care—especially when patients experience reflux, bloating, altered bowel habits, malnutrition or other gastrointestinal symptoms.
But gut-directed care should complement, not replace, established treatment of pulmonary fibrosis.
The future of the gut–lung field may ultimately depend not on the broad concept of “leaky gut,” but on identifying specific barrier defects, microbial metabolites and immune pathways that can be measured, validated and therapeutically targeted.
That is where this emerging science may eventually become clinically meaningful.
About Dr. Samar Shadly
Dr. Samar Shadly is a Consultant Pulmonologist and Certified Functional Medicine Practitioner, with advanced subspecialty training in interstitial lung disease, pulmonary fibrosis, pulmonary hypertension and lung transplantation at the University of Toronto.
Her clinical and academic interests include Integrative and Functional Pulmonology, the gut–lung axis, pulmonary fibrosis, autoimmune-associated interstitial lung disease, nutrition, metabolic health and emerging microbiome science.
Looking for a Comprehensive Approach to Pulmonary Fibrosis or ILD?
If you are living with pulmonary fibrosis or another form of interstitial lung disease and would like a comprehensive assessment that considers your pulmonary disease together with relevant gastrointestinal, nutritional, metabolic and lifestyle factors, you can explore the available online consultation options.
An integrative assessment may help identify clinically relevant gastrointestinal or nutritional issues while remaining firmly anchored to evidence-based pulmonary care.
Contact us through the consultation page or WhatsApp to learn more about online consultation options.
Functional and integrative care is intended to complement—not replace—appropriate pulmonary treatment, including antifibrotic or immunomodulatory therapy when indicated.
Medical Disclaimer: This article is for educational purposes only and does not constitute individualized medical advice. Patients with pulmonary fibrosis or interstitial lung disease should remain under appropriate specialist pulmonary care.
Related Topics
Gut–Lung Axis and Pulmonary Fibrosis: Can Gut Health Affect Lung Fibrosis?
Gut Dysbiosis and Pulmonary Fibrosis: What Does the Evidence Show?
SCFAs and Pulmonary Fibrosis
Butyrate and Lung Fibrosis
Tryptophan Metabolism and Pulmonary Fibrosis
Probiotics and Pulmonary Fibrosis
Gut Microbiome and Interstitial Lung Disease
SIBO and Systemic Sclerosis
GERD, Microaspiration and Pulmonary Fibrosis